Format

Send to

Choose Destination
See comment in PubMed Commons below
Hepatology. 2015 Nov;62(5):1623-32. doi: 10.1002/hep.27934. Epub 2015 Jul 30.

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

Author information

  • 1Forum for Collaborative HIV Research, University of California at Berkeley, Washington, DC.
  • 2Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products, US Food and Drug Administration, Silver Spring, MD.
  • 3Merck Research Laboratories, West Point, PA.
  • 4Vertex Pharmaceuticals, Inc., Boston, MA.
  • 5Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • 6Janssen Infectious Diseases, Beerse, Belgium.
  • 7Bristol-Myers Squibb Research and Development, Wallingford, CT.
  • 8Gilead Sciences, Inc., Foster City, CA.
  • 9Data First Consulting, Inc., Belmont, CA.
  • 10AbbVie, Inc., Chicago, IL.

Abstract

Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct-acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials.

CONCLUSION:

This report provides a comprehensive, systematic review of all resistance information available from sponsors' trials as a tool to inform the HCV drug development field.

PMID:
26095927
DOI:
10.1002/hep.27934
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center